Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function
Update: 2020-08-11
Description
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.08.10.243154v1?rss=1
Authors: Palanikumar, L., Karpauskaite, L., Hassan, S., Alam, M., Al-Sayegh, M., Chehade, I., Maity, D., Ali, L., Falls, Z., Samudrala, R., Kalmouni, M., Hunashal, Y., Ahmed, J., Karapetyan, S., Pasricha, R., Esposito, G., Afzal, A. J., Hamilton, A. D., Kumar, S., Magzoub, M.
Abstract:
Missense mutations in p53 are severely deleterious and occur in over 50% of all human cancers. The vast majority of these mutations are located in the inherently unstable DNA-binding domain (DBD), many of which destabilize the domain further and expose its aggregation-prone hydrophobic core, prompting self-assembly of mutant p53 into inactive cytosolic amyloid-like aggregates. Screening an oligopyridylamide library, previously shown to inhibit amyloid formation associated with Alzheimer's disease and type II diabetes, identified a tripyridylamide, ADH-6, that potently abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. Moreover, ADH-6 effectively targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. Notably, ADH-6 treatment substantially shrinks xenografts harboring mutant p53 and prolongs survival, while exhibiting no toxicity to healthy tissue. This study demonstrates the first successful application of a bona fide small-molecule amyloid inhibitor as an anticancer agent.
Copy rights belong to original authors. Visit the link for more info
http://biorxiv.org/cgi/content/short/2020.08.10.243154v1?rss=1
Authors: Palanikumar, L., Karpauskaite, L., Hassan, S., Alam, M., Al-Sayegh, M., Chehade, I., Maity, D., Ali, L., Falls, Z., Samudrala, R., Kalmouni, M., Hunashal, Y., Ahmed, J., Karapetyan, S., Pasricha, R., Esposito, G., Afzal, A. J., Hamilton, A. D., Kumar, S., Magzoub, M.
Abstract:
Missense mutations in p53 are severely deleterious and occur in over 50% of all human cancers. The vast majority of these mutations are located in the inherently unstable DNA-binding domain (DBD), many of which destabilize the domain further and expose its aggregation-prone hydrophobic core, prompting self-assembly of mutant p53 into inactive cytosolic amyloid-like aggregates. Screening an oligopyridylamide library, previously shown to inhibit amyloid formation associated with Alzheimer's disease and type II diabetes, identified a tripyridylamide, ADH-6, that potently abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. Moreover, ADH-6 effectively targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. Notably, ADH-6 treatment substantially shrinks xenografts harboring mutant p53 and prolongs survival, while exhibiting no toxicity to healthy tissue. This study demonstrates the first successful application of a bona fide small-molecule amyloid inhibitor as an anticancer agent.
Copy rights belong to original authors. Visit the link for more info
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
